Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
31. |
ECCT/20/10/01 | HIV-CORE 006 A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa. |
Principal Investigator(s) 1. Eduard J Sanders Site(s) in Kenya 1. KEMRI Mtwapa Research Clinic (Kilifi county) 2. KAVI-ICR Nairobi (Nairobi City county) |
19-11-2020 |
View |
32. |
ECCT/20/06/09 | HIV-CORE 006 A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa |
Principal Investigator(s) 1. Professor Walter Jaoko, Jaoko, Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. KEMRI/ Wellcome Trust Research Programme (Kilifi county) |
09-09-2020 |
View |
33. |
ECCT/25/07/01 | FIH Study of CLY-124 A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) 2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) |
18-12-2025 |
View |
34. |
ECCT/25/08/09 | First-in-human (FIH) study A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Dr Lucas Tina Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) 2. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) |
17-09-2026 |
View |
35. |
ECCT/23/11/04 | AUB Study A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy. |
Principal Investigator(s) 1. Dr Alice Kaaria Site(s) in Kenya Kenyatta National Hospital (KNH) |
15-04-2024 |
View |
36. |
ECCT/14/02/03 | A Phase 1/2 Randomized, Double-Blind, Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus pneumoniae Whole Cell Vaccine Formulated with Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers (12-15 Months of Age) |
Principal Investigator(s) 1. Nekoye Namungu Otsyula 2. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kombewa Clinical Research Center |
14-02-2014 |
View |
37. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
09-02-2016 |
View |
38. |
ECCT/23/10/02 | MATRIX-001 protocol A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
11-01-2024 |
View |
39. |
ECCT/25/12/03 | ITU512 Study - Site 6002 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Doreen Terry Karimi Mutua Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |
40. |
ECCT/25/12/02 | ITU512 Study - Site 6003 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |